Theravance Biopharma, Inc. (TBPH)
Develops inhalers and pills to treat lung disease and low blood pressure conditions
$16.89+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+55.0%
The outlook
TBPH is trading roughly midway through its 52-week range with a neutral analyst outlook. The average price target sits about 5% above the current price, while the stock shows mixed momentum against its moving averages. With a trailing P/E of 7.6, the valuation appears relatively modest compared to broader markets.
What’s behind the score
Price trendMixed vs its moving averages
52-week range59% of the way from its 52-week low to high
Price targetAvg target +5% vs current price
Analyst price target
~12-month · 3 analysts$17.67average target+4.6% vs now
Now $16.89
Low $17.00High $19.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$875.4M
52-wk high
$21.03
52-wk low
$10.82
50-day avg
$16.65
200-day avg
$17.00
Trailing P/E
7.6